Miyeon Kim Email & Phone Number

Seoul, South Korea

Genuone Sciences is South Korea’s top CMO pharmaceutical company, specializing in the full range of services for formulation development, manufacturing and clinical development capabilities. Our optimized solutions provide proven, effective and safe medicines and pharmaceuticals of the highest quality.

Gangnam-Gu, Seoul, Korea

 Developed growth plans, strategic imperatives and transformation plans; Assessed the dynamics of the external environment including pricing reform policies and identified capability gaps to fulfill while laying down infrastructure and governance to pursue further growth opportunities Identified the growth drivers in innovative pipelines; PanOptix, multi focal IOLs for Surgical business unit and Dailies Total 1 contact lens for Vision Care unit and formed launch strategies to maximize the market opportunities to prime the products to its full potential.  Developed and executed organization and operational transformation plans and business model changes to drive internal and external changes Translated vision into people, process and system requirements as part of transformation planning. Defined new roles and competencies to advance the organizational readiness for fast evolving healthcare environment and evolving portfolio Imbued compelling vision and mission to the organization by instilling a culture of entrepreneurial ownership and accountability Laid out substantial foundation for reentering the Dry Eye portfolio to best leverage local CMO strategies while identifying region and global sourcing opportunities Spearheaded spin-offs after assessing operational readiness and successfully managed the spin off at the country level. Led the business model transition to 3PL for the transformation (ERP adaption)

Korea

 Provided leadership in redefining the cardio metabolic portfolio and the growth strategies of new resource planning to sustain the mature brands while leveraging the customer facing platform to launch a new innovative Heart Failure medicine, Entresto.  Drove double-digit growth of diabetic portfolio in a highly competitive market environment

Greater New York City Area

Responsible for general management of 90 + mature and post LOE brands and customer-facing capabilities of Sales, Payer Strategy and Consumer Engagement Team  Sustaining market leadership of mature brands. Developing Peri LOE strategy of upcoming LOE assets  Deploying innovative cost offset programs for LOE portfolios Successfully addressing surged demand of late stage portfolio caused by competitors’ supply disruptions

Greater New York City Area

Led US Brands Team. Identified numerous innovative ways to compete in the established U.S. pharmaceutical market  Managed the P&L of US Brands Team: Attained exceptional financial performance over two years by rejuvenating mature products and containing erosion of post LOE brands Responsible for executing Lipitor US LOE strategy Led the promotion of mature products of Relpax, Estring, Nicotrol and Tikosyn with optimized resources to sustain market leadership. Developed and implemented various innovative opportunistic programs for the late stage portfolio  Built strategic platform for long term sustainable growth Built a robust pipeline to drive growth of BU–Acquisition and launch of an ADHD medicine in ER Liquid and Chewable form  Demonstrated focused leadership in creating ownership culture and people development Lead by example to espouse the virtues of culture. Created INNOVATOR award to recognize colleagues including partners who exemplify OWN IT behaviors  Led many cross-national, cross-functional BUs, nurturing collaboration across countries and cultures to share best practices and to cross-pollinate ideas

Jung-Gu, Seoul, Korea

Led EP Korea business vision, strategy and transformation planning. Established framework of maximizing the base business while setting up frameworks to realize Gx opportunity in Korea. Drove unprecedented double digit growth of Post LOE brands including Lipitor, Caduet, Neurontin, Zoloft and Xalatan by executing thorough business strategies while focusing on optimizing resources  Led the Korea EP business with striking record of double digit growth  Drove unprecedented double digit growth of established products: Lipitor, Caduet, Neurontin, Zoloft and Xalatan  Managed smooth transition of Legacy Wyeth products (Effexor, Tazocin and oral contraceptives) Completed Market Evolution Response Strategic Review to develop EPBU Korea’s response to the changing market environment, and established the strategic framework of EP business in Korea Completed Strategic Workforce Plan to develop an approach to organizational transition in response to the changing market environment and EPBU strategy Defined the vision of the organization and imbued dynamic culture to enhance engagement and drive performance  Imbued compelling vision and mission to the organization and encouraged entrepreneurial culture Achieved one of the highest engagement score within EPBU and Pfizer: all areas at well above 85 percentile Translated future state into people, process and system requirements as part of transformation planning Passionately focused on identifying key talents and talent development. Deployed active talent selection process and sponsored various development initiatives to develop global talents. Expanded the talents' responsibilities and capabilities into new roles for development

Jung-Gu, Seoul, Korea

Led CV Portfolio Marketing Team to refine the portfolio strategies and growth vision per product. Managed LOE of Norvasc, Lipitor and Caduet; sustained market leadership of Norvasc, defended Lipitor and Caduet market share and grew back by double digit. Formed partnership with Novartis to launch Exforge; successfully launched Exforge, and grew the product as the number-one fixed dose combination of ARB and CCB in 2 years

Korea

Developed organization-wide data analytics capabilities and executed new recruitment and development initiatives of marketing talents. Built integrated operation functions to support Sales and Marketing

Korea

Defined the vision of Lipitor as a critical growth driver of Pfizer Korea and implemented strategic growth road map. Successfully managed the cardiovascular issue of Celebrex triggered by Vioxx recall and put Celebrex back into growth trajectory with 45% during the product management period

Korea

Supported Country Manger to build transformative five-year strategic plan of Pfizer Korea. Led a task force team to develop Pfizer Korean vision and implementation plans

Master Of Business Administration (Mba), Strategy And Marketing

Master Of Arts (M.A.), Communications Studies

Bachelor Of Arts (B.A.), English Language And Literature/Letters